UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study

European journal of cancer (1990), 2017-02, Vol.72, p.S38-S38

2017

Volltextzugriff (PDF)

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

The New England journal of medicine, 2015-11, Vol.373 (21), p.2005-2014

2015

Volltextzugriff (PDF)

Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S210-S210

2010

Volltextzugriff (PDF)

CYP2C83 increases risk of neuropathy in breast cancer patients treated with paclitaxel

Annals of oncology, 2013-06, Vol.24 (6), p.1472-1478

2013

Volltextzugriff (PDF)

a phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors

Cytotherapy (Oxford, England), 2021-05, Vol.23 (5), p.S95-S96

2021

Volltextzugriff (PDF)

Outcomes of Patients With HER2-Positive Breast Cancer Metastatic to Brain Treated With HER2-Targeted Systemic Therapy and Stereotactic Radiosurgery

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.e580-e580

2021

Volltextzugriff (PDF)

Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor

European journal of cancer (1990), 2020-10, Vol.138, p.S11-S12

2020

Volltextzugriff (PDF)

Hematopoietic Stem/Progenitor Cells and Engineering: A PHASE 1, FIRST IN HUMAN (FIH) STUDY OF ADENOVIRALLY TRANSDUCED AUTOLOGOUS MACROPHAGES ENGINEERED TO CONTAIN AN ANTI-HER2 CHIMERIC ANTIGEN RECEPTOR (CAR) IN SUBJECTS WITH HER2 OVEREXPRESSING SOLID TUMORS

Cytotherapy (Oxford, England), 2022-05, Vol.24 (5), p.S26-S27

2022

Volltextzugriff (PDF)

340P - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)

Annals of oncology, 2019-10, Vol.30, p.v121-v122

2019

Volltextzugriff (PDF)

Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)

Annals of oncology, 2019-10, Vol.30, p.v121-v122

2019

Volltextzugriff (PDF)

Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx

Annals of oncology, 2019-10, Vol.30, p.v854

2019

Volltextzugriff (PDF)

LBA18 - Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx

Annals of oncology, 2019-10, Vol.30, p.v854-v854

2019

Volltextzugriff (PDF)

KEYNOTE-012: A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple-negative breast cancer (mTNBC)

Annals of oncology, 2015-05, Vol.26, p.iii6-iii6

2015

Volltextzugriff (PDF)

243 - Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study

European journal of cancer (1990), 2017-02, Vol.72, p.S38-S38

2017

Volltextzugriff (PDF)

A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies

Annals of oncology, 2016-10, Vol.27, p.vi134-vi134

2016

Volltextzugriff (PDF)

NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)

Annals of oncology, 2018-10, Vol.29, p.viii453-viii453

2018

Volltextzugriff (PDF)

280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States

European journal of cancer supplements, 2008, Vol.6 (12), p.90-91

2008

Volltextzugriff (PDF)

415 POSTER Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations

European journal of cancer supplements, 2008, Vol.6 (12), p.130-131

2008

Volltextzugriff (PDF)

PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)

Annals of oncology, 2012-09, Vol.23, p.ix153-ix154

2012

Volltextzugriff (PDF)

442O - PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)

Annals of oncology, 2012-09, Vol.23, p.ix153-ix154

2012

Volltextzugriff (PDF)

2020

International journal of radiation oncology, biology, physics, 2006-11, Vol.66 (3), p.S220-S221

2006

Volltextzugriff (PDF)

2020: Phase I/II Trial of Herceptin Plus Radiotherapy for Chemotherapy-Refractory Locally Advanced or Recurrent Breast Cancer

International journal of radiation oncology, biology, physics, 2006, Vol.66 (3), p.S220-S221

2006

Volltextzugriff (PDF)

Implications for Treatment of Variations in Length of the First Metacarpal in Different Types of Triphalangeal Thumbs

The Journal of hand surgery, European volume, 2010-01, Vol.35 (1), p.65-69

2010

Volltextzugriff (PDF)

The Effect of the Epiphyseal Growth Plate on the Length of the First Metacarpal in Triphalangeal Thumb

The Journal of hand surgery (American ed.), 2006-09, Vol.31 (7), p.1183-1188

2006

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Hematology, Oncology And Palliative Medicine
(4)
Humans
(4)
Life Sciences & Biomedicine
(4)
Science & Technology
(4)
Biological And Medical Sciences
(3)
Female
(3)
Medical Sciences
(3)
Adult
(2)
Aged
(2)
Breast Neoplasms - Drug Therapy
(2)
Breast Neoplasms - Genetics
(2)
Diseases Of The Osteoarticular System
(2)
Growth Plate
(2)
Metacarpal Length
(2)
Middle Aged
(2)
Orthopedics
(2)
Surgery
(2)
Thumb - Abnormalities
(2)
Triphalangeal Thumb
(2)
Tumors
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Phase I Study and Biomarker Analysis of Lapatinib and Concurrent Radiation for Locally Advanced Breast Cancer

CYP2C83 increases risk of neuropathy in breast cancer patients treated with paclitaxel

a phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors

Outcomes of Patients With HER2-Positive Breast Cancer Metastatic to Brain Treated With HER2-Targeted Systemic Therapy and Stereotactic Radiosurgery

Phase 1/2 study of the safety and efficacy of APL-101, a specific c-MET inhibitor

Hematopoietic Stem/Progenitor Cells and Engineering: A PHASE 1, FIRST IN HUMAN (FIH) STUDY OF ADENOVIRALLY TRANSDUCED AUTOLOGOUS MACROPHAGES ENGINEERED TO CONTAIN AN ANTI-HER2 CHIMERIC ANTIGEN RECEPTOR (CAR) IN SUBJECTS WITH HER2 OVEREXPRESSING SOLID TUMORS

340P - Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)

Dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)

Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx

LBA18 - Clinical outcomes by chemotherapy regimen in patients with RS 26-100 in TAILORx

KEYNOTE-012: A phase Ib study of pembrolizumab (MK-3475) in patients (pts) with metastatic triple-negative breast cancer (mTNBC)

243 - Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study

A dose-escalation study of weekly intravenous CRLX301 in patients with advanced solid tumor malignancies

NCI 9922: Phase II study of ibrutinib in treatment-refractory distant metastatic cutaneous melanoma (DMCM)

280 POSTER Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States

415 POSTER Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations

PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)

442O - PI3K Kinase Inhibitor GSK2126458 (GSK458): Clinical Activity in Select Patient (PT) Populations Defined by Predictive Markers (STUDY P3K112826)

2020

2020: Phase I/II Trial of Herceptin Plus Radiotherapy for Chemotherapy-Refractory Locally Advanced or Recurrent Breast Cancer

Implications for Treatment of Variations in Length of the First Metacarpal in Different Types of Triphalangeal Thumbs

The Effect of the Epiphyseal Growth Plate on the Length of the First Metacarpal in Triphalangeal Thumb

Suchergebnisse filtern